LPCN 1144 not checked

Lipocine Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
4 active
8 in total · 6 in the EU
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“Oral LPCN 1144 + d-alpha tocopherol total daily dose of 450 mg testosterone undecanoate + 476 mg d-alpha tocopherol administered as 225 mg testosterone undecanoate + 238 mg d-alpha tocopherol BID”In the company’s words, NCT04134091 on ClinicalTrials.gov
Tested for
Nonalcoholic Steatohepatitis (NASH), NASH - Nonalcoholic Steatohepatitis
Main trialPhase 2
“This is a Phase 2, randomized, double-blind, placebo controlled, three arm study in adult men with biopsy confirmed NASH. The study is aimed at evaluating efficacy and tolerability of LPCN 1144 in adult men with NASH.”In the company’s words, NCT04134091 on ClinicalTrials.gov
Other names
testosterone undecanoate

Other drugs for Nonalcoholic Steatohepatitis (NASH)

All 30 drugs for Nonalcoholic Steatohepatitis (NASH)

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials8

TrialPhaseCompletesWhat it tests
Phase 2Completed 24 Jun 2021 The Efficacy, Safety and Tolerability of Oral LPCN 1144 in Subjects With Nonalcoholic Steatohepatitis
Phase 2Completed 1 Mar 2022 A Study of the Safety and Tolerability of LPCN 1144 in Subjects Who Completed the LPCN 1144-18-002 Trial
Phase 2Ended not given Does human skeletal muscle possess an epigenetic memory of testosterone
Phase 4Authorised not given A 52 week prospective randomized controlled study to investigate the effect of intramuscular testosterone undecanoate supplementation vs placebo on intrahepatic fat content in obese men with uncontrolled type 2 diabetes (T2DM) suffering from hypogonadism with a subsequent 108 week open label phase to investigate long term effects on lipid distribution and cardiometabolic parameters in all participating men.
Phase 4Ended not given Muscle strength and -mass after bariatric surgery - a possible effect of testosterone replacement therapy? Randomized, placebo-controlled and double-blinded study
Phase 2Authorised not given TestOsterone TreatmEnt on Neuroprotection and Myelin Repair in Relapsing Remitting Multiple Sclerosis (TOTEM-RRMS)
Phase 2Authorised not given Endocrinological Support Therapy After Military Operations
Phase 2Authorised not given SEMAGONA: A randomized four-arm parallel group double-blind double dummy 52-week clinical trial comparing the effects of s.c. Semaglutide 2.4 mg once-weekly, i.m. testosterone undecanoate 1,000 mg every 13th week, combination of s.c. Semaglutide 2.4 mg once-weekly and i.m. testosterone undecanoate 1,000 mg every 13th week, and placebo on body composition and hypogonadal symptoms in men with obesity-associated functional hypogonadism
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow LPCN 1144

Following is part of Solo: you see every change to LPCN 1144 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in